Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma

Autor:	Yasushi Takamatsu, Kenji Ishitsuka, Hidenori Sasaki, Hiroo Katsuya, Junji Suzumiya, Kazuo Tamura, Takao Shibata
Rok vydání:	2009
Předmět:	Adult Male Cancer Research Vincristine medicine.medical_specialty Cyclophosphamide Prednisolone CHOP Pneumocystis carinii Gastroenterology Polymerase Chain Reaction Risk Assessment Antibodies Monoclonal Murine-Derived immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Lymphocyte Count DNA Fungal Pneumonitis Aged Retrospective Studies business.industry Lymphoma Non-Hodgkin Antibodies Monoclonal Hematology Middle Aged medicine.disease Non-Hodgkin's lymphoma Regimen Oncology Doxorubicin Immunology Rituximab Female business Lung Diseases Interstitial medicine.drug
Zdroj:	Leukemialymphoma. 50(11)
ISSN:	1029-2403
Popis:	There are a few reports suggesting that rituximab (RTX) might be a risk for interstitial pneumonitis (IP). We also experienced such patients in the era of RTX. Here, we reviewed all the patients with non-Hodgkin lymphoma who were treated with RTX-CHOP-like regimen (R-CHOP) to determine the risk of developing IP. One of 59 (1.7%) patients who received CHOP alone and 8 of 129 (6.2%) patients who were treated with R-CHOP experienced IP (p = 0.28). Furthermore, three of eight patients who have had IP during R-CHOP were confirmed having Pneumocystis jirovecii pneumonia (PCP). PCP occurred during the fourth, sixth, and seventh cycle of chemotherapy, respectively. Among the patients treated by R-CHOP, 3 of 32 (9%) patients whose lymphocyte counts were1000/microL before chemotherapy developed PCP, while 70 patients whose lymphocyte counts were1000/microL did not (p = 0.03). In four of eight patients, IP occurred during the administration of granulocyte-colony stimulating factor. RTX seems to have a certain risk to induce IP including PCP. Patients with lymphoma who were treated by R-CHOP regimen, might be considered as PCP prophylactic, especially if the number of lymphocytes is low at the beginning of chemotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::432cac3d1be5ba1ce6fa78e6be810be6 https://pubmed.ncbi.nlm.nih.gov/19863173 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.